Stockscreener 앱 받기
31.17
0.87%
0.27
시간 외 거래:
31.19
0.02
+0.06%
전일 마감가:
$30.90
열려 있는:
$30.5
하루 거래량:
1.25M
Relative Volume:
0.98
시가총액:
$1.79B
수익:
$11.13M
순이익/손실:
$-81.99M
주가수익비율:
-17.33
EPS:
-1.7988
순현금흐름:
$-68.38M
1주 성능:
-6.73%
1개월 성능:
+6.93%
6개월 성능:
+368.72%
1년 성능:
+155.07%
1일 변동 폭
$29.40
$31.25
1주일 범위
$29.40
$33.00
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
31.17 | 1.77B | 11.13M | -81.99M | -68.38M | -1.7988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Growth Review: Is Capricor Therapeutics Inc a defensive stock2026 EndofYear Setup & Long-Term Safe Return Strategies - baoquankhu1.vn
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Capricor Therapeutics Pipeline Overview: Deramiocel for Muscular Dystrophy and Exosome-Based Vaccine Development (2025-2026) - Minichart
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insight - GuruFocus
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - 富途牛牛
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Insider Monkey
Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26) - TradingView
Deramiocel DMD program and big Nippon Shinyaku deals at Capricor (NASDAQ: CAPR) - Stock Titan
About Capricor Therapeutics (Ondo Tokenized) - Coinbase
13 Best Hot Stocks to Buy According to Analysts - Insider Monkey
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript - Insider Monkey
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data - Sahm
Q1 Earnings Forecast for CAPR Issued By HC Wainwright - MarketBeat
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? - Yahoo Finance
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative - simplywall.st
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $ - GuruFocus
Capricor Therapeutics Nears Key Milestones After Earnings Call - TipRanks
Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics (CAPR) Shares Recommended for Purchase Ami - GuruFocus
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss - marketscreener.com
B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $63 | CAPR Stock News - GuruFocus
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
CAPR: Piper Sandler Raises Price Target to $58, Reiterates Overw - GuruFocus
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3%Time to Sell? - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler - MarketBeat
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
Trading the Move, Not the Narrative: (CAPR) Edition - Stock Traders Daily
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR) - The Globe and Mail
Cantor Fitzgerald Remains a Buy on Capricor Therapeutics (CAPR) - The Globe and Mail
B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating - marketscreener.com
Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone - MSN
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - Sahm
Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial Challenges - GuruFocus
Capricor Therapeutics (CAPR) Advances Duchenne Therapy with FDA Review - GuruFocus
Capricor Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Capricor (CAPR) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts - Investing.com Nigeria
Capricor Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Capricor Therapeutics Q4 2025 misses EPS forecasts By Investing.com - Investing.com UK
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Capricor Looks Ahead To Deramiocel Approval In DMD - Citeline News & Insights
Capricor Therapeutics falls on Q4 earnings miss By Investing.com - Investing.com Canada
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):